Therapies on the Horizon for Diabetic Kidney Disease

Sadaf S. Khan*, Susan E. Quaggin

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Diabetic nephropathy is rapidly becoming the major cause of end-stage renal disease and cardiovascular mortality worldwide. Standard of care therapies include strict glycemic control and blockade of the renin-angiotensin-aldosterone axis. While these treatments slow progression of diabetic nephropathy, they do not arrest or reverse it. Newer therapies targeting multiple molecular pathways involved in renal inflammation, fibrosis, and oxidative stress have shown promise in animal models. Subsequently, many of these agents have been investigated in clinical human trials with mixed results. In this review, we will discuss recent findings of novel agents used in the treatment of diabetic nephropathy.

Original languageEnglish (US)
Article number111
JournalCurrent diabetes reports
Issue number12
StatePublished - Dec 1 2015


  • Bardoxolone
  • Diabetic nephropathy
  • TGF-β

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Therapies on the Horizon for Diabetic Kidney Disease'. Together they form a unique fingerprint.

Cite this